Serum homocysteine, dehydroepiandrosterone sulphate and lipoprotein (a) in Alzheimer's disease and vascular dementia

Aging and Disease

Volumn 4, Issue 2, 2013, Pages 57-64

  Ray, Lopamudra ^a   Khemka, Vineet Kumar ^a   Behera, Prajna ^a   Bandyopadhyay, Kausik ^a   Pal, Sandip ^b   Pal, Keya ^a   Basu, Debasis ^a   Chakrabarti, Sasanka ^a  

^a INSTITUTE OF POST GRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

^b BANGUR INSTITUTE OF NEUROSCIENCES   (India)

Author keywords

Alzheimer's disease; Dehydroepiandrosterone sulphate; Differential diagnosis; Homocysteine; Lipoprotein (a); Vascular dementia

Indexed keywords

EID: 84890521380     PISSN: None     EISSN: 21525250     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Groves WC, Brandt J, Steinberg M, Warren A, Rosenblatt A, Baker A, Lyketsos CG (2000). Vascular dementia and Alzheimer's disease: is there a difference? A comparison of symptoms by disease duration. J Neuro Psychiatry Clin Neurosci, 12: 305-315.
2. Kalaria RN, Maestre GE, Arizaga R, Friedland RP, Galasko D, Hall K, et al (2008). Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factors. Lancet Neurol, 7: 812-826.
3. Lobo A, Launer LJ, Fratiglioni L, Andersen K, Di Carlo A, Breteler MM, et al (2000). Prealence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology, 54: S4-S9.
4. Swerdlow RH (2007). Pathogenesis of Alzheimer's disease. Clin Interv Aging, 2: 347-359.
5. Román GC (2003). Vascular dementia: distinguishing characteristics, treatment, and prevention. J Am Geriatr Soc, 51: S296-S304.
6. Francis P (2006). Targeting cell death in dementia. Alzheimer Dis Assoc Disord, 20: S3-S7.
7. Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H, Winblad B, Blennow K (2001). Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol, 58: 373-379.
8. Spies PE, Slats D, Sjögren JM, Kremer BP, Verhey FR, Rikkert MG, Verbeek MM (2010). The cerebrospinal fluid amyloid beta42/40 ratio in the differentiation of Alzheimer's disease from non-Alzheimer's dementia. Curr Alzheimer Res, 7: 470-476.
9. de Jong D, Jansen RW, Kremer BP, Verbeek MM (2006). Cerebrospinal fluid amyloid beta42/ phosphorylated tau ratio discriminates between Alzheimer's disease and vascular dementia. J Gerontol A Biol Sci Med Sci, 61: 755-758.
10. Nägga K, Gottfries J, Blennow K, Marcusson J (2002). Cerebrospinal fluid phospho-tau, total tau and beta-amyloid (1-42) in the differentiation between Alzheimer's disease and vascular dementia. Dement Geriatr Cogn Disord, 14: 183-190.
11. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino RB, Wilson PW, Wolf PA (2002). Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med, 346: 476-483.
12. Ravaglia G, Forti P, Maioli F, Martelli M, Servadei L, Brunetti N, Porcellini E, Licastro F (2005). Homocysteine and folate as risk factors for dementia and Alzheimer disease. Am J Clin Nutr, 82: 636-643.
13. Leblhuber F, Walli J, Artner-Dworzak E, Vrecko K, Widner B, Reibnegger G, Fuchs D (2000). Hyperhomocysteinemia in dementia. J Neural Transm, 107: 1469-1474.
14. Naylor JC, Hulette CM, Steffens DC, Shampine LJ, Ervin JF, Payne VM, et al (2008). Cerebrospinal fluid dehydroepiandrosterone levels are correlated with brain dehydroepiandrosterone levels, elevated in Alzheimer's disease, and related to neuropathological disease stage. J Clin Endocrinol Metab, 93: 3173-3178.
15. Aldred S, Mecocci P (2010). Decreased dehydroepiandrosterone (DHEA) and dehydro-epiandrosterone sulfate (DHEAS) concentrations in plasma of Alzheimer's disease (AD) patients. Arch Gerontol Geriatr, 51: e16-e18.
16. Panza F, D'Introno A, Colacicco AM, Capurso C, Pichichero G, Capurso SA, Capurso A, Solfrizzi V (2006). Lipid metabolism in cognitive decline and dementia. Brain Res Rev, 51: 275-292.
17. Emanuele E, Peros E, Tomaino C, Feudatari E, Bernardi L, Binetti G, Maletta R, Micieli G, Bruni AC, Geroldi D (2004). Relation of apolipoprotein (a) size to Alzheimer's disease and vascular dementia. Dement Geriatr Cogn Disord, 18: 189-196.
18. Zhuo JM, Wang H, Praticò D (2011). Is hyperhomocysteinemia an Alzheimer's disease (AD) risk factor, an AD marker, or neither? Trends Pharmacol Sci, 32: 562-571.
19. Chacón IJ, Molero AE, Pino-Ramírez G, Luchsinger JA, Lee JH, Maestre GE (2009). Risk of dementia associated with elevated plasma homocysteine in a latin american population. Int J Alzheimers Dis, 2009, pii: 632489.
20. Malaguarnera M, Ferri R, Bella R, Alagona G, Carnemolla A, Pennisi G (2004). Homocysteine, vitamin B12 and folate in vascular dementia and in Alzheimer disease. Clin Chem Lab Med, 42: 1032-1035.
21. de la Torre JC (2002). Alzheimer disease as a vascular disorder: nosological evidence. Stroke, 33: 1152-1162.
22. Kalaria RN, Ballard C (1999). Overlap between pathology of Alzheimer disease and vascular dementia. Alzheimer Dis Assoc Disord, 13: S115-123.
23. Miller JW, Green R, Mungas DM, Reed BR, Jagust WJ (2002). Homocysteine, vitamin B6, and vascular disease in AD patients. Neurology, 58: 1471-1475.
24. Ho PI, Ortiz D, Rogers E, Shea TB (2002). Multiple aspects of homocysteine neurotoxicity: glutamate excitotoxicity, kinase hyperactivation and DNA damage. J Neurosci Res, 70: 694-702.
25. Jara-Prado A, Ortega-Vazquez A, Martinez-Ruano L, Rios C, Santamaria A (2003). Homocysteine-induced brain lipid peroxidation: effects of NMDA receptor blockade, antioxidant treatment, and nitric oxide synthase inhibition, Neurotox Res, 5: 237-243.
26. Oldreive CE, Doherty GH (2007). Effects of nitric oxide on the survival and neuritogenesis of cerebellar Purkinje neurons. Neurosci Lett, 413: 52-57.
27. Zhuo JM, Praticò D (2010). Normalization of hyperhomocysteinemia improves cognitive deficits and ameliorates brain amyloidosis of a transgenic mouse model of Alzheimer's disease. FASEB J, 24: 3895-3902.
28. den Heijer T, Vermeer SE, Clarke R, Oudkerk M, Koudstaal PJ, Hofman A, Breteler MM (2003). Homocysteine and brain atrophy on MRI of non-demented elderly. Brain, 126: 170-175.
29. Aisen PS, Schneider LS, Sano M, Diaz-Arrastia R, van Dyck CH, Weiner MF, Bottiglieri T, Jin S, Stokes KT, Thomas RG, Thal LJ (2008). High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. JAMA, 300: 1774-1783.
30. Tsimikas S, Hall JL (2012). Lipoprotein (a) as a potential causal genetic risk factor of cardiovascular disease: a rationale for increased efforts to understand its pathophysiology and develop targeted therapies. J Am Coll Cardiol, 60: 716-721.
31. Berglund L, Ramakrishnan R (2004). Lipoprotein(a): an elusive cardiovascular risk factor. Arterioscler Thromb Vasc Biol, 24: 2219-2226.
32. Panza F, D'Introno A, Colacicco AM, Capurso C, Pichichero G, Capurso SA, Capurso A, Solfrizzi V (2006). Lipid metabolism in cognitive decline and dementia. Brain Res Rev, 51: 275-292.
33. Maninger N, Wolkowitz OM, Reus VI, Epel ES, Mellon SH (2009). Neurobiological and neuropsychiatric effects of dehydroepiandrosterone (DHEA) and DHEA sulfate (DHEAS). Front Neuroendocrinol, 30: 65-91.
34. Rammouz G, Lecanu L, Papadopoulos V (2011). Oxidative Stress-Mediated Brain Dehydro-epiandrosterone (DHEA) Formation in Alzheimer's Disease Diagnosis. Front Endocrinol, 2: 69.
35. Brown RC, Han Z, Cascio C, Papadopoulos V (2003). Oxidative stress-mediated DHEA formation in Alzheimer's disease pathology. Neurobiol Aging, 24: 57-65.
36. Yanase T, Fukahori M, Taniguchi S, Nishi Y, Sakai Y, Takayanagi R, Haji M, Nawata H (1996). Serum dehydroepiandrosterone (DHEA) and DHEA-sulfate (DHEA-S) in Alzheimer's disease and in cerebrovascular dementia. Endocr J, 43: 119-123.
37. Kim SB, Hill M, Kwak YT, Hampl R, Jo DH, Morfin R (2003). Neurosteroids: Cerebrospinal fluid levels for Alzheimer's disease and vascular dementia diagnostics. J Clin Endocrinol Metab, 88:5199-206.
38. Hillen T, Lun A, Reischies FM, Borchelt M, Steinhagen-Thiessen E, Schaub RT (2000). DHEA-S plasma levels and incidence of Alzheimer's disease. Biol Psychiatry, 47: 161-163.
39. Kimonides VG, Khatibi NH, Svendsen CN, Sofroniew MV, Herbert J (1998). Dehydroepiandrosterone (DHEA) and DHEA-sulfate (DHEAS) protect hippocampal neurons against excitatory amino acid-induced neurotoxicity. Proc Natl Acad Sci U S A, 95: 1852-1857.
40. Kurata K, Takebayashi M, Morinobu S, Yamawaki S (2004). β-estradiol, dehydroepiandrosterone, and dehydroepiandrosterone sulfate protect against N-methyl-D-aspartate-induced neurotoxicity in rat hippocampal neurons by different mechanisms. J Pharmacol Exp Ther, 311: 237-245.
41. Rammouz G, Lecanu L, Aisen P, Papadopoulos V (2011). A lead study on oxidative stress-mediated dehydroepiandrosterone formation in serum: the biochemical basis for a diagnosis of Alzheimer's disease. J Alzheimers Dis, 24: 5-16.
42. Ryan RA, Carrol J (1976). Studies on a 3-beta-hydroxysteroid sulphotransferase from rat liver. Biochim Biophys Acta, 429: 391-401.